Back to News
Market Impact: 0.35
What Genmab A/S (GMAB) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Genmab reported 22% revenue growth for the first nine months of 2026 and expects full-year revenue in the upper part of its existing guidance range. Sales of EPKINLY and royalty income supported the growth.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
GMAB0.55
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook